Plain-English translation of NCT06430541 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This clinical trial is testing whether —a psychedelic compound—combined with professional therapy can help reduce the fear of cancer recurrence in women who have been treated for early-stage breast cancer or ovarian cancer and are now cancer-free. Researchers want to see if this medication, given in a safe, supervised setting alongside counseling, can ease anxiety, depression, and improve overall quality of life for cancer survivors.
Many cancer survivors struggle with persistent fear that their cancer will return, even when they are doing well medically. This anxiety can significantly affect their quality of life, and current treatments don't always help everyone. This trial is exploring whether this medication might offer a new way to address this very real emotional burden.
You likely qualify if…
You likely don't qualify if…
You would attend several preparatory therapy sessions to get ready for the experience. Then, on a designated day in a monitored, comfortable medical setting, you would receive the medication while trained therapists support you. Afterward, you would attend four follow-up therapy sessions to help you process and integrate the experience. Throughout the study, you would complete questionnaires about your anxiety, mood, fear of recurrence, and overall quality of life.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States